Drugs / 131 I-Metaiodobenzylguanidine (131 I-MIBG)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01163383 | — | neuroblastoma, pheochromocytoma-paraganglioma | John Maris | Available | No outcome recorded |
| — | NCT01377532 | — | paraganglioma, pheochromocytoma | University of California, San Francisco | Approved for marketing | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131 I-Metaiodobenzylguanidine (131 I-MIBG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01163383 ↗ |
| Route | Intravenous | “The 131I-MIBG will be given through an intravenous catheter over 1-2 hours.” NCT01163383 ↗ |